ReviewFrontiers in cell and developmental biology2025
Chromatin remodeling complexes: architects influencing breast cancer progression.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the most common types of cancer, breast cancer strongly contributes to the increase in morbidity and mortality worldwide. Alterations in the genetic and epigenetic landscape contribute to the complexity and heterogeneity of the disease, making its understanding and prognosis more challenging. Chromatin remodeling complexes are implicated as essential factors driving the progression and aggressiveness of breast cancer by permitting chromatin dynamics to promote or suppress transcription. Based on their structure and biochemical properties, chromatin remodeling complexes are divided into four subfamilies: SWI/SNF, ISWI, CHD and INO80. Due to their involvement in breast cancer progression, these complexes present potential therapeutic targets, either through direct or indirect approaches. Several promising efforts have been made to develop targeted therapies against chromatin remodeling complexes using specific ATPase inhibitors or proteasome-based degraders to control tumour growth. Further research is needed to elucidate the interplay between the remodeling complexes, their co-regulators, and interacting partners, in order to understand their mechanisms and develop their potential for therapeutic strategies, especially in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.